Brain-derived neutrophic factor genetic polymorphism Val66Met and response to fluoxetine and venlafaxine in patients with major depressive disorder

Trial Profile

Brain-derived neutrophic factor genetic polymorphism Val66Met and response to fluoxetine and venlafaxine in patients with major depressive disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2010

At a glance

  • Drugs Fluoxetine (Primary) ; Venlafaxine (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top